Light Chain Calibrator Quantification Amid Polyclonal Background
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying monoclonal immunoglobulins and free light chains in samples are limited by high background concentrations of polyclonal bound light chains, leading to insensitivity and false negatives, particularly in diseases like multiple myeloma and AL amyloidosis.
Innovation Solution
Utilizing kappa or lambda light chains as calibrators in mass spectrometry to quantify the opposite light chain by mixing a predetermined amount of lambda or kappa light chain calibrator with the sample, allowing for accurate quantitation through mass spectrometry techniques like LC-MS or MALDI-TOF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to quantify immunoglobulins and free light chains, then the measurement can be performed, but the sensitivity is poor due to high background concentrations of polyclonal bound light chains causing false negatives
Solution Approach 1:
The patent extracts and removes polyclonal bound light chains from the sample through immunopurification using specific antibodies before mass spectrometry analysis. This extraction step eliminates the harmful background interference that causes false negatives, allowing sensitive detection of monoclonal immunoglobulins and free light chains at concentrations as low as 0.1 g/L
Solution Approach 2:
The patent uses an intermediary substance - a specific antibody - that mediates between the sample and the detection system. This antibody selectively binds to polyclonal bound light chains, enabling their removal from the sample while leaving monoclonal immunoglobulins and free light chains intact for accurate quantification
2Measurement precision
If mass spectrometry is used to quantify light chains, then accurate quantitation is achieved, but the method becomes complex requiring specific calibrators and preparation steps
Solution Approach 1:
The patent creates a simplified copy of the complex quantification process by using a calibrator substance that mimics the target analyte. The calibrator contains known amounts of monoclonal immunoglobulins and free light chains in a matrix that replicates the sample characteristics, allowing accurate quantitation through a standardized comparison process that reduces methodological complexity
3Reliability
If polyclonal bound light chains are present in the sample, then the sample represents a complete immunoglobulin profile, but the background concentration interferes with detection of monoclonal proteins
Solution Approach 1:
The patent applies local quality by treating different components of the immunoglobulin profile differently. Through selective immunopurification, polyclonal bound light chains are removed from the detection zone while monoclonal immunoglobulins and free light chains are preserved. This creates a localized clean detection environment that maintains reliability by detecting only the clinically relevant monoclonal proteins without interference from polyclonal background
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a sensitive and accurate method for quantifying kappa and lambda light chains, reducing interference from polyclonal background chains and improving detection of monoclonal immunoglobulins, especially in conditions like multiple myeloma and AL amyloidosis.
Implementation Method 1
performing mass spectrometry on the mixture
Data Source
AI summary
The invention provides a method of quantifying the amount of kappa or lambda immunoglobulin light chain in a sample from a subject comprising: i. providing a sample from a subject; ii. mixing the sample with a predetermined amount of lambda light chain calibrator or kappa light chain calibrator to form a mixture; iii. performing mass spectrometry on the mixture; and iv. quantifying one or both of a) the amount of lambda light chain in the sample by comparing the relative amount of lambda light chain in the mixture as determined by the mass spectrometry to the relative amount of calibrator kappa light chain in the mixture as determined by mass spectrometry; and/or b) the amount of kappa light chain in the sample by comparing the relative amount of kappa light chain in the mixture as determined by mass spectrometry to the relative amount of calibrator lambda light chain in the mixture as determined by mass spectrometry, most typically MALDI-TOF spectrometry or liquid chromatography-mass spectrometry.